Individual plans may vary and formulary information changes.Contact the applicable plan provider for the most current information.
For many people, these improve within weeks of starting an antidepressant.
In some cases, however, antidepressants cause side effects that don't go away.
Talk to your doctor or mental health provider about any side effects you're having.
Depending on your heart health and the type of antidepressant you take, periodically you may need an electrocardiogram (ECG) to monitor what's called the QT interval to be sure there is no prolonged interval before or during treatment that could increase your risk of serious irregular heart rhythms (arrhythmia).
If side effects seem intolerable, you may be tempted to stop taking an antidepressant or to reduce your dose on your own. Your symptoms may return, and stopping your antidepressant suddenly may cause withdrawal-like symptoms.
Xerostomia (4-9%) Constipation (3-6%) Fatigue (2-8%) Libido decrease (3-7%) Anorgasmia (2-6%) Flatulence (2%) Toothache (2%) Weight gain (1%) Menstrual disorder (2%) Neck/shoulder pain (3%) Rhinitis (5%) Flu-like syndrome (5%) Ejaculation disorder (9-14%) Arthralgia Abdominal pain Abnormal bleeding Abnormal dreams Allergy Blurred vision Bronchitis Chest pain Constipation Decreased appetite Decreased concentration Disrupts platelets/hemostasis Dizziness Dyspepsia Fever Heartburn Hot flashes Impotence Irritability Jaw stiffness Lethargy Lightheadedness Menstrual disorder Hypertension Palpitations Migraine Myalgia Paresthesia Rash Sweating Tinnitus Tremor Urinary frequency Urinary tract infection Vertigo Vomiting Yawning 65 years Drug is not FDA appored for treatment of bipolar depression In children and young adults, the risks must be weighed against the benefits of taking antidepressants Patients should be monitored closely for changes in behavior, clinical worsening, and suicidal tendencies; this should be done during initial 1-2 months of therapy and dosage adjustments The patient’s family should communicate any abrupt changes in behavior to the health-care provider Worsening behavior and suicidal tendencies that are not part of the presenting symptoms may require discontinuation of therapy This drug is not approved for use in pediatric patients Conflicting evidence regarding use of SSRIs during pregnancy and increased risk of persistent pulmonary hypertension of the newborn, or PPHN (see Pregnancy) In neonates exposed to SNRIs/SSRIs late in third trimester: risk of complications such as feeding difficulties, irritability, and respiratory problems Caution with seizure disorder, bipolar mania, severe renal impairment; not FDA approved for the treatment of bipolar depression NRIs/SSRIs have been associated with the development of SIADH; hyponatremia has been reported rarely May worsen psychosis in some patients and precipitate a shift to mania or mypomania in patients with bipolar disorder Risk of hyponatremia Risk of mydriasis; may trigger angle closure attack in patients with angle closure glaucoma with anatomically narrow angles without a patent iridectomy Bone fractures are associated with antidepressant therapy; consider the possibility of a fracture in patients with unexplained bone pain, swelling, or bruising Prescriptions should be written for smallest quantity consistent with good patient care and the family or care giver alerted to monitor patient for emergence of suicidality and associated behaviors (anxiety, agitation, panic attacks, insomnia, hostility, akathisia, impulsivity, irritabilty) SSRIs/SNRIs increase risk of abnormal bleeding (further increased if concomitant aspirin, NSAIDs or anticoagulants, or hemorrhagic diathesis) Prolongation of QT interval and ventricular arrhythmias reported, especially in female patients with preexisting QT prolongation or other risk factors Risk of cognitive and motor function impairment; use caution when operating heavy machinery Use with caution in patients with history of seizure disorders or or conditions predisposing to seizures including brain damage and alcoholism May impair platelet aggregation that can result in increased risk of bleeding events including GI bleeding especially if taken concomitantly with aspiring, warfarin, or NSAIDs Risk of serotonin syndrome or neuroleptic malignant syndrome (NMS)-like reactions have been reported with SSRIs and SNRIs, including desvenlafaxine, both when taken alone, but especially when co-administered with other serotonergic agents (including triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, tryptophan, buspirone, amphetamines, and St.
John’s Wort); if symptoms occur, discontinue therapy and initiate supportive treatment; if concomitant use of desvenlafaxine with other serotonergic drugs is clinically warranted, patients should be made aware of increased risk for serotonin syndrome, particularly during treatment initiation and dose increases No additional benefits at 20 mg/day May cause or exacerbate sexual dysfunction Gradually taper dose before discontinuation; abrupt discontinuation may cause dysphoric mood, dizziness, sensory disturbances, agitation, confusion, anxiety, headache, insomnia, tinnitus, seizures, irritability The above information is provided for general informational and educational purposes only.There was a reduction in risk of suicidality with antidepressants compared with placebo in adults 65 years of age and older.Depression and certain other psychiatric disorders are themselves associated with increases in the risk of suicide.Anyone considering the use of Lexapro or any other antidepressant in a child or adolescent must balance this risk with the clinical need.Short-term studies did not show an increase in the risk of suicidality with antidepressants compared with placebo in adults beyond 24 years of age.In order to avoid these symptoms, the dose of SSRI can be slowly reduced instead of abruptly stopped.